NCT05263609 2022-08-02Optimizing Pembrolizumab Therapy With Timing and Intensification With AxitinibUniversity of OklahomaPhase 2 Withdrawn
NCT01441388 2011-12-20A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.PfizerPhase 1 Withdrawn